Conflict of interest: Nothing to declare.
Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed disease following surgery alone†
Version of Record online: 5 NOV 2012
Copyright © 2012 Wiley Periodicals, Inc.
Pediatric Blood & Cancer
Volume 60, Issue 3, pages 512–514, March 2013
How to Cite
Sokol, E., Haut, P. R., Gosiengfiao, Y., Feinstein, K., Pytel, P. and Cohn, S. L. (2013), Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed disease following surgery alone. Pediatr. Blood Cancer, 60: 512–514. doi: 10.1002/pbc.24385
- Issue online: 15 JAN 2013
- Version of Record online: 5 NOV 2012
- Manuscript Accepted: 3 OCT 2012
- Manuscript Received: 31 AUG 2012
- Little Heroes Cancer Research Foundation
- Neuroblastoma Children's Cancer Society
- Super Jake Foundation
- Elise Anderson Neuroblastoma Research Fund
- refractory neuroblastoma;
- relapsed neuroblastoma;
Outcome for the vast majority of high-risk neuroblastoma patients with refractory or relapsed disease is dismal. We report two high-risk patients who remain progression-free for more than 113 and 18 months following the diagnosis of refractory/relapsed disease who were treated with surgery alone. Complete resolution of a refractory thoracic mass and relapsed liver nodules was observed in one patient. The refractory/relapsed disease in the second patient has remained stable. In both cases, the tumor showed histologic evidence of neuroblastoma maturation. These cases demonstrate that refractory/relapsed neuroblastoma is clinically heterogeneous and highlight the need for better biomarkers to optimize patient care. Pediatr Blood Cancer 2013; 60: 512–514. © 2012 Wiley Periodicals, Inc.